PTC Therapeutics released data regarding its drug dubbed PTC518 tested against HD. Read why I rate PTCT stock a Sell at this point.

Wells Fargo raised PTC Therapeutics, Inc. PTCT price target from $68 to $74. Wells Fargo analyst Tiago Fauth maintained an ...

Notably, the PTC Therapeutics, Inc. (NASDAQ:PTCT) share price has gained 51% in three years, which is better than the average market return. More recently the stock has gained 20% in a year, which isn ...

The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events ...

PTC Therapeutics, a global biopharmaceutical leader in rare diseases, has launched a Middle East and North Africa (MENA) office at Dubai Science Park to enhance access to transformative medicines for ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2025 Earnings Call Transcript May 6, 2025 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $10.04, expectations were $-1.08. Operator ...

WARREN, N.J., April 25, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

Also Read: PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington’s Program Phenylketonuria is an inherited disorder that increases the levels of a substance ...

Nearly six months ago, PTC Therapeutics reported positive interim data for a drug in mid-stage development for Huntington’s disease, an inherited neurological disorder with limited treatment ...

Sept 28 (Reuters) - PTC Therapeutics (PTCT.O), opens new tab said on Thursday it plans to cut 25% of its workforce, as the drugmaker aims to reduce its yearly operating expenses. The workforce ...

March 28 (Reuters) - PTC Therapeutics (PTCT.O), opens new tab said on Friday its inherited progressive muscle-wasting disorder drug will no longer be available for sale in the EU as the European ...